Skip to main
  1. Stocks
  2. argenx
  3. Forecast
ARGX

argenx (ARGX) Stock Forecast & Price Target

argenx (ARGX) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 53%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

argenx is fundamentally attractive because its lead franchise keeps compounding: 3Q26 VYVGART sales reached about $1.72 billion, up 14% quarter over quarter and 53% year over year, with strong growth in both MG and CIDP, high access levels, and added convenience from the prefilled syringe. The company also shows meaningful pipeline depth, with ALKIVIA meeting its primary endpoint in autoimmune myositis, an IMNM sBLA expected by year-end, a Phase III celiac move for FB102, and multiple catalysts in 2026-27 that broaden the growth base beyond one product. Financially, 3Q26 net income was about $506 million on $1.751 billion of operating income, while $3.7 billion in cash and durable commercialization reduce funding risk and support continued investment.

Bears say

argenx is exposed to significant execution risk because Vyvgart’s growth may fall short, and expansion into oMG, ITP, myositis, and Sjogren’s could ultimately fail to convert into meaningful incremental revenue. Its valuation is also vulnerable to clinical, regulatory, or commercial setbacks for efgartigimod and ARGX-117, including unforeseen safety signals in ongoing trials, which could weaken confidence in the broader platform. Competition and macro headwinds such as FX, inflation, shipping risks, tariffs, and other R&D or regulatory disruptions further pressure the downside case and undermine long-term fundamental support.

argenx (ARGX) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 53% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.

argenx (ARGX) Analyst Forecast & Price Prediction

Get the latest argenx (ARGX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in argenx (ARGX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About argenx (ARGX) Forecast

Analysts have given argenx (ARGX) a Buy based on their latest research and market trends.

According to 17 analysts, argenx (ARGX) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,156.76, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,156.76, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

argenx (ARGX)


argenx (ARGX) Analyst Forecast & Price Prediction

Get the latest argenx (ARGX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in argenx (ARGX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ARGX stock data and trends